Kaoskey seeks to work with partners worldwide to apply its powerful biological signal analysis capabilities to develop digital diagnostic and therapeutic products for improved patient care.
Over the past five years the Kaoskey team has been developing its patented mathematical and signal processing methodologies for non-stationary (‘chaotic’) signal analysis and decomposition.
We have focused our technology development on two core tasks.
The major results include:
Clinical Application Development
Kaoskey has developed commercial products for both preclinical researchers and clinical patients.
Our ASSYST software replaces the arduous task of manually assessing long term video-EEG recording to find seizures – it rapidly processes this data to find seizures with validated gold standard accuracy.
It is currently sold around the world for preclinical research with rodent data; and is in clinical trials for detecting absence seizures in humans.
Our new TRIO software detects and logs seizures using a single channel ECG.
It is being developed to be a wearable smartphone-based device that offers a novel and discrete method of monitoring / logging / alerting epileptic events when they occur.
Automated Rodent Seizure Detection Software
Our first commercial product using our technology for the assessment of EEGs was launched at SfN in 2018. The ASSYST software system provides rapid automated detection of seizures and other epileptogenic events (SWDs, HFOs, etc) in long-term rodent EEG recordings. ASSYST is now being used by leading pre-clinical research institutions around the world.
Human Automated Seizure Detection
Clinical validation trials are nearing completion for our new TRIO system. A breakthrough development which applies our non-stationary signal analysis tools to automated and accurate detection, logging and alerting of seizures in humans with epilepsy.